Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazolas - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimycotics sisteminiam vartojimui - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 ir 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 ir 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invazinių aspergillosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b arba itraconazole, arba pacientams, kurie netoleruoja tokių vaistų;- fusariosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, arba pacientams, kurie netoleruoja amphotericin b;- chromoblastomycosis ir mycetoma pacientams, sergantiems liga, kuri yra ugniai atsparios į itraconazole, arba pacientams, kurie netoleruoja itraconazole;- coccidioidomycosis pacientams, sergantiems liga, kuri yra ugniai atsparios į amphotericin b, itraconazole ar fluconazole, arba pacientams, kurie netoleruoja tokių vaistų;- burnos ir ryklės kandidozė: kaip pirmos eilės gydymas pacientams, kurie serga sunkia liga ar yra imuninės sistemos sutrikimų, į kuriuos atsako į aktualius terapija, tikimasi, bus prastas. atsparumą apibrėžiamas kaip progresavimo infekcija ar nesugebėjimo pagerinti po mažiausiai 7 dienas, prieš terapinės dozės efektyvus priešgrybelinis gydymas. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

ge healthcare as - flutemetamolis (18f) - radionuclide imaging; alzheimer disease - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. vizamyl yra radioaktyvieji preparatai, vaistai nurodė, pozitronų emisijos tomografijos (pet) vaizdo atkūrimo β amiloido neuritic apnašas tankis yra smegenys suaugusių pacientų, kurių pažinimo funkcijos sutrikimas, kuris yra įvertinami alzheimerio liga (ad) ir kitų priežasčių, pažinimo funkcijos sutrikimas. vizamilis turėtų būti vartojamas kartu su klinikiniu įvertinimu. neigiamas skenavimas rodo, retas ar ne plokštelės, kuri yra nesuderinama su diagnoze ad.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh - acidum cis-aconiticum d8/acidum ascorbicum d6/acidum citricum d8/acidum fumaricum d8/acidum alpha-ketoglutaricum d8/acidum malicum d8/acidum succinicum d8/adenosinum triphosphoricum d10/beta vulgaris rubra d6/coenzym a d8/cysteinum d6/nadidum d8/natrium pyruvicum d8/natrium riboflavinum phosphoricum d6/nicotinamidum d6/pulsatilla pratensis d6/pyridoxinum hydrochloricum d6/sulfur d10/thiaminum hydrochloricum d6/acidum thiocticum d6/barium oxalsuccinicum d10/cerium oxalicum d8/hepar sulfuris d10/magnesium oroticum dihydricum d6/manganum phosphoricum d6/natrium diethyloxalaceticum d6 - tabletės - 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg; 1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 mg/1 m

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - kiti nervų sistemos vaistai - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biologische heilmittel heel gmbh (vokietija) - injekcinis tirpalas - acidum ascorbicum d6 – 0,05 ml; natrium riboflavinum phosphoricum d6 – 0,05 ml; thiaminum hydrochloricum d6 – 0,05 ml; pyridoxinum hydrochloricum d6 – 0,05 ml; nicotinamidum d6 – 0,05 ml; acidum cis-aconiticum d8 – 0,05 ml; acidum citricum d8 – 0,05 ml; acidum fumaricum d8 – 0,05 ml; acidum alpha-ketoglutaricum d8 – 0,05 ml; acidum dl-malicum d8 – 0,05 ml; acidum succinicum d8 – 0,05 ml; barium oxalsuccinicum d10 – 0,05 ml; natrium pyruvicum d8 – 0,05 ml; cysteinum d6 – 0,05 ml; pulsatilla pratensis d6 – 0,05 ml; hepar sulfuris d10 – 0,05 ml; sulfur d10 – 0,05 ml; adenosinum triphosphoricum d10 – 0,05 ml; nadidum d8 – 0,05 ml; coenzymum a d8 – 0,05 ml; beta vulgaris conditiva d4 – 0,05 ml; natrium diethyloxalaceticum d6 – 0,05 ml; manganum phosphoricum d6 – 0,05 ml; magnesium oroticum d6 – 0,05 ml; cerium oxalicum d8 – 0,05 ml; acidum alpha-liponicum d6 – 0,05 ml; excipients q.s. ad 5 ml - fluconazolsvampedrabende.site fluconazol uden recept arkliams, galvijams, kiaulėms, avims, ožkoms, šunims ir katėms fermentams aktyvinti sergant degeneracinėmis ligomis, sutrikus fermentų veiklai, deguonies įsisavinimui gerinti sergant medžiagų apykaitos, sekinančiomis ligomis, lėtine egzema.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran natrio - amiloidozė, Šeimyniniai - kiti nervų sistemos vaistai - onpattro fluorouracilu gydyti paveldimų transthyretin tarpininkaujant amiloidozė (hattr amiloidozė) suaugusiems pacientams, sergantiems 1 ir 2 etapų polyneuropathy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

beevital gmbh - oksalo rūgštis dihidratas, skruzdžių rūgštis - ektoparazitocidinės medžiagos vietiniam vartojimui, įsk. insekticidai - bitės - varrozės (varroa destructor) gydymas medaus bičių kolonijose su arkliais ir be jų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

dany bienenwohl gmbh - oksalo rūgštis dihidratas - ektoparazitocidinės medžiagos vietiniam vartojimui, įsk. insekticidai - bitės - gydymo varroosis (varroa destructor) medaus bitės (apis mellifera) perų-nemokamai kolonijų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

dany bienenwohl gmbh - oksalo rūgštis dihidratas - ectoparasiticides for topical use, incl. insecticides, ectoparaciticides, insecticides and repellents - honey bees - gydymo varroosis (varroa destructor) medaus bitės (apis mellifera) perų-nemokamai kolonijų.